Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7636534 | 0.89 | ALDH1A1 (0.48) | KMT2AALDH1A1GAAMEN1GFER | |
| SCHEMBL7630166 | 0.82 | ALDH1A1 (0.42) | KMT2AALDH1A1GAAMEN1GFER | |
| SCHEMBL8163013 | 0.81 | GFER (0.46) | KMT2AALDH1A1GAAMEN1GFER | |
| SCHEMBL8163011 | 0.81 | GFER (0.43) | KMT2AALDH1A1GAAMEN1GFER | |
| SCHEMBL2979188 | 0.81 | KMT2A (0.57) | KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL7632379 | 0.79 | ALDH1A1 (0.41) | KMT2AALDH1A1GAAMEN1GFER | |
| SCHEMBL7931629 | 0.78 | ALDH1A1 (0.53) | KMT2AALDH1A1GAAMEN1GFER | |
| SCHEMBL7632391 | 0.77 | KMT2A (0.51) | KMT2AALDH1A1GAAMEN1GFER | |
| SCHEMBL20472061 | 0.76 | ENPP1 (0.57) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL20472175 | 0.75 | AKR1C3 (0.50) | KMT2AALDH1A1GAAMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6459001-B1 | Tricyclic compounds, their preparation process and the intermediates of this process, their use as medicaments and the pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2002-10-01 | — | — | US | disclosed |
| US-6221907-B1 | Tricyclic compounds having activity specific for integrins, particularly alphanubeta3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same | HOECHST MARION ROUSSEL (FR) | 2001-04-24 | — | — | US | disclosed |